Understanding how B-cell type acute leukaemia is diagnosed involves knowing when to seek medical attention and what tests doctors use to confirm this fast-growing blood cancer. Early detection through proper diagnostic methods can help doctors start treatment quickly and improve outcomes for both children and adults facing this serious but often treatable condition.
Introduction: Who Should Undergo Diagnostics and When to Seek Testing
B-cell acute lymphoblastic leukaemia, often called B-ALL, is a cancer that affects the blood and bone marrow. The disease develops quickly, sometimes over just days or weeks, which means recognising when something is wrong becomes very important.[2] Anyone experiencing persistent symptoms should not ignore them, especially if they last longer than two weeks without improvement.[5]
This condition is most common in young children, particularly those between ages two and five, but adults can develop it too. Around 75% of all B-ALL cases affect children younger than six years old.[2] For adults, the disease is less common but still serious, with about 75% to 80% of all adult acute lymphoblastic leukaemia cases being the B-cell type.[5]
You should seek medical attention if you or your child experiences several concerning symptoms that don’t go away. These warning signs happen because the bone marrow produces too many abnormal, immature B-cells called lymphoblasts, which are white blood cells that normally help fight infections. When these abnormal cells multiply and crowd the bone marrow, they prevent the body from making enough healthy blood cells.[2]
Common symptoms that should prompt a visit to the doctor include unusual fatigue that doesn’t improve with rest, frequent infections that keep coming back, and unexplained bruising or bleeding. You might notice nosebleeds that happen often or bleeding gums, even with gentle brushing. Some people develop tiny red or purple spots on their skin called petechiae, which look like pinpoint dots scattered across the body.[5]
Other symptoms include fever that persists without an obvious cause, night sweats that soak through clothing, and unexpected weight loss even when eating normally. Pain in the bones or joints can occur, especially in children who might start limping or complaining that their legs hurt. Swollen lymph nodes in the neck, armpits, or groin area are another sign, though these swellings are usually painless.[2]
Children might also show decreased appetite, difficulty breathing, or pain in the abdomen. This abdominal discomfort can happen when the liver or spleen becomes enlarged as abnormal B-cells build up in these organs.[2] In some cases, the cancer can spread to the brain, spinal cord, or in boys, the testicles, though this is less common at the time of initial diagnosis.[2]
Parents should trust their instincts when it comes to their children’s health. If a child seems unwell in ways that don’t match typical childhood illnesses, or if symptoms persist despite rest and basic care, seeking medical attention is always the right choice. Healthcare providers will start with a thorough physical examination and ask detailed questions about medical history, symptoms, and how long they’ve been present.[2]
For adults over age 50 and children under 15, the risk of developing acute lymphoblastic leukaemia is slightly higher than for other age groups.[5] People with certain genetic conditions, such as Down syndrome or Fanconi anaemia, face increased risk and should be particularly attentive to symptoms. Those who have been exposed to radiation or who have received previous chemotherapy treatment also have elevated risk.[2]
Classic Diagnostic Methods Used to Identify B-Cell ALL
Diagnosing B-cell acute lymphoblastic leukaemia requires a combination of tests that work together to confirm the presence of cancer, determine its type, and assess how far it has spread. The diagnostic process usually begins with the simplest tests and moves toward more detailed examinations as needed.[2]
Physical Examination and Medical History
The first step in diagnosis is a comprehensive physical examination performed by a doctor. During this exam, the healthcare provider will check for physical signs of leukaemia, such as pale skin, bruises, or bleeding. They will feel the neck, underarms, and groin to check for swollen lymph nodes, and will gently press on the abdomen to detect whether the liver or spleen feels enlarged.[2]
The doctor will ask detailed questions about symptoms, including when they started, how severe they are, and whether they’re getting worse. They’ll inquire about medical history, including any previous cancer treatments, radiation exposure, or genetic conditions in the family. This conversation helps the doctor understand the complete picture of a patient’s health.[2]
Blood Tests
Blood tests are usually the next step and often the first indication that something serious might be happening. These tests, called full blood counts or complete blood counts, measure the numbers of different types of blood cells circulating in the body.[7]
In people with B-ALL, blood tests typically reveal abnormal numbers of white blood cells. Sometimes there are too many white blood cells, but paradoxically, these cells don’t work properly. Other times, despite the cancer affecting white blood cells, the total white blood cell count might actually be low. The blood tests also usually show too few red blood cells, which causes anaemia and explains the fatigue and pale appearance, and not enough platelets, which leads to easy bruising and bleeding.[2]
Laboratory technicians examine a small sample of blood smeared onto a glass slide under a microscope. They look for abnormal-looking lymphocytes that appear immature, with an indistinct nucleus and reduced amount of cytoplasm. These abnormal cells are the blast cells that characterise acute leukaemia.[7] However, blood tests alone cannot definitively diagnose B-ALL; they can only suggest that further testing is needed.[15]
Doctors also use blood tests to check how well the liver and kidneys are functioning and to detect signs of inflammation or infection throughout the body.[2]
Bone Marrow Aspiration and Biopsy
A bone marrow test is the most reliable and common method for confirming a diagnosis of B-ALL.[2] This procedure involves taking samples of bone marrow, usually from the hip bone, using a thin, hollow needle. The hip bone is chosen because it contains a large amount of bone marrow and is relatively easy to access safely.[5]
The procedure typically happens in two parts. During bone marrow aspiration, the doctor uses a needle to withdraw a small amount of liquid bone marrow. During bone marrow biopsy, a slightly larger needle removes a small piece of solid bone tissue along with the marrow inside it. Often both procedures are done at the same time.[15]
Before the procedure, the area is numbed with a local anaesthetic to reduce pain. Some patients, especially children, might receive additional pain relief or sedation. Patients should speak up if they have concerns about pain or need more medication to feel comfortable during the procedure.[7]
Once the bone marrow samples are collected, they are sent to a laboratory where specialists examine them under a microscope. They count the number of blast cells present and look at their size, shape, and other physical features. For a diagnosis of acute leukaemia, the bone marrow typically contains more than 20% blast cells, though this percentage can be much higher in many cases.[14]
Laboratory doctors also perform special tests on the bone marrow cells to determine exactly what type of leukaemia is present. They use techniques that identify specific proteins on the cell surface called antigens. B-cell leukaemia cells typically express certain markers like CD10, CD19, and CD34 on their surface, along with an enzyme called terminal deoxynucleotide transferase, or TdT, inside the nucleus.[14]
These laboratory specialists also look for genetic changes in the leukaemia cells. Between 60% and 80% of patients with B-ALL have abnormalities in their chromosomes or mutations in their genes.[7] One particularly important genetic change is the Philadelphia chromosome, which occurs when parts of chromosome 9 and chromosome 22 break off and swap places. This creates a new abnormal gene that produces a protein encouraging leukaemia cells to grow and multiply. About 20% to 30% of adults with ALL have this Philadelphia-positive type, which is more common in older people.[3]
Understanding these genetic and molecular features helps doctors predict how the disease might behave and determines which treatments will work best. This information becomes crucial for developing a personalised treatment plan.[15]
Lumbar Puncture or Spinal Tap
A lumbar puncture, also called a spinal tap, is performed to check whether leukaemia cells have spread to the fluid surrounding the brain and spinal cord. This fluid is called cerebrospinal fluid or CSF.[2]
During this procedure, the patient typically lies on their side with knees drawn up toward the chest. A doctor inserts a thin needle between two vertebrae in the lower back, specifically in the lumbar region between the L4 and L5 bones. This allows them to collect a small amount of cerebrospinal fluid without touching the spinal cord itself.[7]
The collected fluid is then examined under a microscope to look for leukaemia cells. Finding cancer cells in the cerebrospinal fluid means the disease has spread to the central nervous system, which requires additional treatment to prevent complications like headaches, seizures, balance problems, or vision changes.[5]
Imaging Tests
While imaging tests cannot diagnose B-ALL on their own, they play an important supporting role in the diagnostic process. These tests help doctors determine the extent of the disease and locate areas where abnormal cells have accumulated.[2]
Several types of imaging may be used depending on what information doctors need. Chest X-rays can reveal enlarged lymph nodes in the chest or show whether the thymus gland, located behind the breastbone, has become enlarged. Computed tomography scans, or CT scans, provide more detailed three-dimensional images that can identify swollen lymph nodes throughout the body and detect enlarged organs like the liver or spleen.[2]
Ultrasound examinations use sound waves to create real-time pictures of internal organs without using radiation. This can be particularly useful for examining the abdomen and checking the size of the liver and spleen.[2] Magnetic resonance imaging, or MRI, uses powerful magnets and radio waves to create detailed images, and is especially helpful for examining the brain and spinal cord if there’s concern about cancer spreading there.[5]
Positron emission tomography scans, called PET scans, can sometimes be used to detect areas of active cancer throughout the body. An echocardiogram, which is an ultrasound of the heart, might be performed to check heart function before starting certain treatments that can affect the heart.[2]
Additional Diagnostic Considerations
For some patients, doctors might recommend a lymph node biopsy if there are significantly enlarged lymph nodes. A small sample of lymph node tissue is removed and examined to confirm the presence of leukaemia cells.[5]
The entire diagnostic process usually happens relatively quickly because B-ALL is an aggressive cancer that can worsen rapidly. Most patients need to start treatment soon after diagnosis is confirmed. The combination of all these test results allows doctors to understand not just whether someone has B-ALL, but also specific characteristics of their disease that will guide treatment decisions.[3]
Diagnostics for Clinical Trial Qualification
Clinical trials are research studies that test new treatments for B-cell acute lymphoblastic leukaemia. These trials are carefully designed with specific criteria about who can participate, called eligibility requirements. The diagnostic tests used to qualify patients for clinical trials are often more extensive and detailed than those used for standard diagnosis.[11]
Before someone can join a clinical trial, researchers need to thoroughly understand their disease characteristics. This ensures that the trial tests the new treatment in the right group of patients and keeps participants as safe as possible. The qualification process typically includes all the standard diagnostic tests described earlier, plus additional specialised examinations.[11]
Measurable Residual Disease Testing
One of the most important tests for clinical trial qualification is measurable residual disease testing, sometimes called minimal residual disease or MRD testing. This extremely sensitive test can detect very small numbers of leukaemia cells that remain in the body after treatment begins, even when standard microscope examination shows no visible cancer cells.[17]
MRD testing uses advanced laboratory techniques to find one leukaemia cell among 10,000 or even 100,000 normal cells. This level of sensitivity is important because the presence or absence of measurable residual disease is the strongest predictor of whether the leukaemia will come back after treatment. Patients with detectable MRD after initial treatment have a much higher risk of relapse than those who achieve MRD-negative status.[17]
Many clinical trials specifically enrol patients based on their MRD status. Some trials test new treatments for patients who have detectable MRD despite responding well by traditional measures. Other trials might compare different treatment approaches to see which one is better at eliminating measurable residual disease.[17]
Comprehensive Genetic and Molecular Testing
Clinical trials often require very detailed genetic and molecular analysis of the leukaemia cells. While standard diagnosis identifies major genetic changes like the Philadelphia chromosome, trial participation may require testing for a broader range of genetic abnormalities and mutations.[7]
Researchers might look for specific chromosome translocations, such as t(4;11) or t(1;19), which involve the rearrangement of genetic material between different chromosomes. They test for mutations in particular genes like CRLF2, NOTCH1, or FBW7. Some trials specifically seek patients with certain genetic features because the treatment being tested targets those particular abnormalities.[7]
For Philadelphia-positive B-ALL, trials might test for specific mutations in the BCR-ABL1 gene that can affect how well certain targeted drugs work. This detailed genetic information helps match patients to trials where they’re most likely to benefit from the experimental treatment.[17]
Functional Status Assessment
Clinical trials need to ensure participants are healthy enough to tolerate the experimental treatment and complete the study. Researchers use standardised scales to assess a person’s functional status, meaning how well they can perform daily activities and take care of themselves.[11]
These assessments look at factors like whether someone can walk, dress themselves, work, or needs assistance with basic tasks. Generally, clinical trials require participants to have reasonably good functional status, though the specific requirements vary depending on what treatment is being tested.[11]
Organ Function Testing
Before joining a clinical trial, patients typically undergo comprehensive testing to check how well their organs are functioning. Blood tests measure liver function by checking levels of certain enzymes and proteins. Kidney function is assessed by measuring substances like creatinine and calculating the glomerular filtration rate.[2]
Heart function testing is particularly important because some leukaemia treatments can affect the heart. An echocardiogram or a heart scan called a MUGA scan measures how efficiently the heart pumps blood. Lung function might be tested with breathing tests called pulmonary function tests.[2]
Clinical trials have specific thresholds for organ function that patients must meet. If someone’s organs have been damaged by previous treatments or other medical conditions, they might not qualify for trials using treatments that could further stress those organs.[11]
Previous Treatment Documentation
For patients who have received prior treatment for B-ALL, clinical trials require detailed documentation of what treatments were given, how the cancer responded, and why previous treatments stopped working or were discontinued. This information helps researchers understand whether the patient’s disease is truly resistant to standard treatments and whether they might benefit from the experimental approach.[9]
Some trials specifically enrol patients with relapsed leukaemia, meaning the cancer came back after an initial response to treatment. Other trials focus on refractory disease, where the leukaemia never responded adequately to initial treatment. About 20% of children with B-ALL experience either relapse or refractory disease, and these patients particularly need new treatment options.[9]
Baseline Symptom and Quality of Life Assessments
Many clinical trials include questionnaires and assessments that measure symptoms and quality of life before treatment begins. These baseline measurements allow researchers to track whether the experimental treatment helps patients feel better and function more normally, not just whether it fights the cancer.[11]
Patients or their caregivers might complete surveys about pain levels, fatigue, ability to eat, sleep quality, and emotional wellbeing. For children, age-appropriate tools assess how leukaemia and its treatment affect school attendance, play activities, and interactions with friends and family.[9]
Research-Specific Procedures
Some clinical trials require additional bone marrow samples, blood draws, or other tissue samples beyond what would normally be collected during standard treatment. These research samples allow scientists to study how the treatment works at a cellular and molecular level. Patients considering clinical trial participation should understand what extra procedures will be required and why they’re necessary for the research.[11]
The diagnostic and qualification process for clinical trials is more rigorous than for standard care, but this thoroughness protects patient safety and ensures the research generates reliable information. Patients who meet all the eligibility criteria and choose to participate in clinical trials gain access to promising new treatments that might work better than current standard options, while also contributing to medical knowledge that will help future patients with B-ALL.[11]
